Introduction
============

Renal cell carcinoma (RCC) is one of the most common cancers, accounting for \>140,000 deaths worldwide each year ([@b1-ol-0-0-11701]). RCC has been considered to be an immunogenic tumor ([@b2-ol-0-0-11701]). Interleukin-2, interferon α and immune checkpoint inhibitors have been used clinically in RCC therapy ([@b3-ol-0-0-11701]--[@b5-ol-0-0-11701]). Novel immunotherapies, such as the combination of anti-programmed death ligand-1 antibody and anti-cytotoxic T-lymphocyte-associated protein 4 antibody, have demonstrated clinical benefit ([@b6-ol-0-0-11701]). However, only a proportion of patients with RCC benefit from the novel immunotherapies ([@b7-ol-0-0-11701]). The immune suppression microenvironment of RCC remains to be investigated.

B7 family member H4 (B7-H4), also known as B7× or B7S1, is one of the members of the B7 superfamily of co-stimulatory molecules and serves as an inhibitory modulator of the T-cell response ([@b8-ol-0-0-11701]). B7-H4 mRNA is widely expressed in human peripheral tissues, but its protein expression in normal tissues seems to be limited ([@b9-ol-0-0-11701]). To date, B7-H4 has been detected in several types of human cancer tissue. In ovarian cancer, B7-H4 expression is associated with tumor-infiltrated antigen-presenting cells (APCs) ([@b10-ol-0-0-11701]). In colorectal carcinoma, B7-H4 facilitates tumor proliferation and metastasis ([@b11-ol-0-0-11701]). The expression of B7-H4 in lung cancer is associated with decreased PFS under nivolumab treatment ([@b12-ol-0-0-11701]). Elevated B7-H4 in breast cancer is associated with an 'immune-cold' microenvironment ([@b13-ol-0-0-11701]). In renal cell carcinoma, intrahepatic cholangiocarcinoma and thyroid cancer, the expression level of B7-H4 is positively associated with tumor progression ([@b14-ol-0-0-11701]--[@b16-ol-0-0-11701]). Previous studies have reported that B7-H4, which is a type I transmembrane glycoprotein, binds to its corresponding receptor on lymphocytes, thus negatively regulating the immune response ([@b8-ol-0-0-11701],[@b17-ol-0-0-11701],[@b18-ol-0-0-11701]). However, certain tumors express B7-H4 protein in intracellular compartments ([@b19-ol-0-0-11701]--[@b22-ol-0-0-11701]). Unlike tumor-associated macrophages, B-cells and dendritic cells (DCs) with membrane expression of B7-H4, tumor cells expressing intracellular B7-H4 do not inhibit T-cell immunity ([@b21-ol-0-0-11701]). Therefore, it appears that intracellular B7-H4 has a distinct biological function to membrane-located B7-H4 ([@b22-ol-0-0-11701],[@b23-ol-0-0-11701]). In order to investigate the biological function of B7-H4 in kidney cancer cells, the present study constructed negative control (NC)/786-O and B7-H4/786-O cell lines, and screened the differentially expressed genes (DEGs) in B7-H4/786-O cells by microarray analysis. The identified DEGs were subsequently validated by western blotting.

Materials and methods
=====================

### Cell culture

The 786-O cell line (catalogue TCHu186) was purchased from the Shanghai Cell Bank of the Shanghai Institute for Biological Sciences. The cells were cultured in RPMI 1640 medium (Gibco, Thermo Fisher Scientific, Inc.) containing 10% fetal bovine serum (Gibco, Thermo Fisher Scientific, Inc.) at 37°C, 5% CO~2~. A total of 1×10^6^ 786-O cells/well in 24-well plates were transfected with 50 µl/well LV5-B7-H4 lentivirus (Genepharma Co., Ltd) or empty vector (Genepharma Co., Ltd) with 5 µg/ml polybrene (Genepharma Co., Ltd) according the manufacturer\'s instructions. The stable expression clones were selected in medium containing 0.5 mg/ml G418 (Thermo Fisher Scientific, Inc.) 24 h post-transfection. After 2 weeks, NC/786-O and B7-H4/786-O stable transgenic cells were obtained and subsequent experiments were performed.

To knock down B7-H4 expression in breast cancer cell line SK-BR-3, 1×10^6^ cells were seeded in 6-well plates 24 h prior to transfection. When the cells reached 70--80% confluence in each well, they were treated with Opti-MEM Reduced Serum Medium (Gibco, Thermo Fisher Scientific, Inc.) containing 50 nM B7-H4 small interfering (si)RNA (Genepharma Co., Ltd) and 10 µl Lipofectamine^®^ 2000 (Invitrogen, Thermo Fisher Scientific, Inc.) for 6 h. The cell supernatant was replaced with fresh medium and cells were cultured for 48 h prior to harvesting and subsequent experiments. The B7-H4 siRNA sequences were as follows: Forward, 5′-GCUGGAGCAAUUGCACUCAUCAUUG(dTdT)-3′ and reverse, 5′-CAAUGAUGAGUGCAAUUGCUCCAGC(dTdT)-3′.

### Microarray processing

For total RNA extraction, NC/786-O and B7-H4/786-O cells were harvested. Triplicate samples were prepared for each cell line. Total RNA was extracted using TRIzol reagent (Invitrogen, Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. Total RNA was quantified using a NanoDrop ND-2000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc.) and the RNA integrity was assessed using an Agilent Bioanalyzer 2100 (Agilent Technologies, Inc.). Total RNA was transcribed into double-stranded cDNA and labeled with cyanine-3-cytidine triphosphate. The labeled cDNAs were hybridized onto Agilent Human Gene Expression microarrays (Agilent Technologies, Inc.). The arrays were scanned by the Agilent Scanner G2505C (Agilent Technologies, Inc.). The heatmap of the gene expression in the two cell lines (triplicates of each cell line) was produced by Multiexperimental Viewer software version 4.8.1 (MeV development team).

### DEG analysis

Feature Extraction software version 10.7.1.1 (Agilent Technologies, Inc.) was used to analyze array images to obtain raw data. GeneSpringGX version 11.0 (Agilent Technologies) was employed for the basic analysis of the raw data, which were normalized with the quantile algorithm. Probes that had ≥10% values in any one of all conditions and had flags in 'Detected' were selected for further data analysis. Genes with fold-change ≥2 and P\<0.05 calculated by unpaired Student\'s t-test between B7-H4/786-O and NC/786-O cells were identified as DEGs.

### Functional enrichment analysis

To explore the functions in which DEGs were enriched in the B7-H4/786-O cell line, the identified DEGs were subjected to functional enrichment analysis with the Datasets for Annotation, Visualization and Integrated Discovery version 6.7 ([david.abcc.Nicfcrf.gov](david.abcc.Nicfcrf.gov)). Gene Ontology (GO) (<http://geneontology.org/>) terms and Kyoto Encyclopedia of Genes and Genome (KEGG) pathways (<https://www.kegg.jp/>) with P\<0.05 were screened out.

### Western blot analysis

NC/786-O and B7-H4/786-O cells were harvested and lysed in RIPA buffer. RIPA cell lysis buffer (cat. no. P0013B) was purchased from Beyotime Institute of Biotechnology. Total proteins were extracted, concentrations were determined by bicinchoninic acid assay, separated using 12% SDS-PAGE (100 µg/lane), and the proteins were transferred onto PVDF membranes. Upon blocking in 5% BSA/PBS buffer at room temperature for 30 min, the membranes were blotted with the primary antibodies at 4°C overnight and subsequently washed with PBS-0.05% (v/v) Tween 20 (PBST) three times. The primary antibodies used were as follows: NME1 (1:500; cat. no. 11086-2-AP, Proteintech Group, Inc.); membrane metalloendopeptidase (MME; 1:500; cat. no 18008-1-AP; Proteintech Group, Inc.); vanin 1 (VNN1; 1:300; cat. no. 21745-1-AP; Proteintech Group, Inc.); matrix metalloproteinase 7 (MMP7; 1:300; cat. no. 10374-2-AP; Proteintech Group, Inc.); tumor necrosis factor α (TNF-α; 1:2,000; cat. no. 60291-1-Ig; Proteintech Group, Inc.); human C-X-C motif chemokine ligand (CXCL) 1/2/3 (1 µg/ml; cat. no. MAB276; R&D Systems, Inc.); CXCL8 (1:500; cat. no. 27095-1-AP; Proteintech Group, Inc.); human C-C motif chemokine ligand 20 (CCL20; 1 µg/ml); cat. no. MAB360; R&D Systems, Inc.); B7-H4 (1:500; cat. no. 12080-1-AP; Proteintech Group, Inc.); β-actin (1: 5,000; cat. no. 66009-1-Ig; Proteintech Group, Inc.) and α-tubulin (1:2,000; cat. no. 11224-1-AP; Proteintech Group, Inc.) were used. Then, the membranes were incubated with the secondary antibodies at room temperature for 1 h and subsequently washed three times with PBST. The secondary antibodies horse anti-mouse IgG (H&L)-horseradish peroxidase (HRP; 1:1,000; cat. no. 7076;) and goat anti-rabbit IgG (H&L)-HRP (1:1,000; cat. no. 7074) were purchased from Cell Signaling Technology, Inc. The membranes were immersed in ECL detection reagent and imaged with a Gel Doc™ EZ system (Bio-Rad Laboratories, Inc.). β-actin or α-tubulin were used as loading controls. The intensities of the bands were determined by Image Lab software version 4.1 (Bio-Rad Laboratories, Inc.). Three independent experiments were performed.

### The Cancer Genome Atlas (TCGA) analysis

RNA-sequencing TCGA data were analysed using the Gene Expression Profiling Interactive Analysis (GEPIA) website ([gepia.cancer-pku.cn/index.html](gepia.cancer-pku.cn/index.html)), which is an interactive web server for analysing RNA-sequencing expression data from TCGA and Genotype-Tissue Expression databases ([@b24-ol-0-0-11701]). The correlation between B7-H4 and the expression of chemokine genes CXCL1, CXCL2, CXCL3, CXCL8 and CCL20 was evaluated by the Pearson\'s correlation test. P\<0.05 was considered to indicate a statistically significant difference.

### Immunohistochemistry (IHC)

The use of clinical samples was approved by the Soochow University Ethical Review Board, and written informed consent was obtained from the patients. A total of 59 specimens fixed with 10% formalin at room temperature for 24 h and embedded in paraffin were collected from the Second Affiliated Hospital of Soochow University were used for IHC analysis. The patients included 36 males and 23 females (mean age, 59 years; age range 39--78 years). All patients had a pathological diagnosis of renal cell carcinoma and underwent radical nephrectomy. Sections (4-µm) were deparaffinized in serial grades of xylene followed by rehydration in sequentially increasing dilutions of ethanol. Upon antigen retrieval was performed by saline sodium citrate (microwave heating for 30 min), endogenous peroxidase was blocked by 3.0% hydrogen peroxide at room temperature for 1 h. Non-specific interactions were blocked using 1.5% blocking serum (Dako, Agilent Technologies, Inc.) in PBS for 10 min at room temperature. Then the sections were incubated with primary antibodies against B7-H4 (1:100; cat. no. 12080-1-AP; Proteintech Group, Inc.); CCL20 (1:200; cat. no. 26572-1-AP; Proteintech Group, Inc.) and CXCL8 (1:200; cat. no. 27095-1-AP; Proteintech Group, Inc.) at 4°C overnight. The sections were then incubated with a HRP-conjugated goat anti-rabbit secondary antibody (1:50; cat. no. GK600705; Gene Tech Co., Ltd.) at room temperature for 1 h. Then the sections were stained by the avidin-biotin immunoperoxidase method. For negative control staining, the primary antibodies were omitted in the procedure. The sections were observed under a light microscope (CX43; Olympus Corporation) at ×400 magnification and evaluated and graded independently by two investigators. The Allred scoring system was used ([@b25-ol-0-0-11701]). The signal intensity was graded from 0 to 3 (0, none; 1, weak; 2, intermediate; and 3, strong), and the percentage of positive tumor cells was scored according to a scale from 1 to 5 (1, \<1; 2, 1--10; 3, 10--30; 4, 30--60; and 5, \>60%). An Allred score of B7-H4 \<80 was designated as B7-H4^low^, while \>80 was designated as B7-H4^high^.

### Mouse and tumor models

Non-obese diabetic/severe combined immunodeficiency mice (age, 4 weeks; male) were purchased from Joinn Laboratories (China), Co., Ltd. Mice were kept in pathogen-free facilities under conventional conditions with controlled temperature (22±2°C) and humidity (55±10%) and 12-h dark/light cycles. The mice were allowed free access to food and water. All animal experiments were approved and conducted in compliance with institutional guidelines established by the Ethics Committee of Soochow University (Suzhou, China). Mice were subcutaneously inoculated into the left axilla with 5×10^6^ 786-O transfected cells suspended in serum-free PBS. Mice were intraperitoneally injected with isotype IgG or anti-CXCL8 antibody once every 3 days at a dose of 1 mg/kg (n=6 mice/group). Tumor growth was assessed twice a week. The orthogonal tumor dimensions were measured with a calliper. The tumor volume was calculated according to the formula V=a × b^2^/2, where V is the volume, a is the maximum diameter and b is the smallest diameter. When the tumor diameter reached 20 mm or tumor volume reached 1,500 mm^3^, the mice were preemptively euthanized by cervical dislocation and the tumor tissues were isolated and weighed. During the present study, the maximum body weight loss is in a mouse due to cachexia was 9.8%, and the longest diameter exhibited by a single subcutaneous tumor was 1.8 cm. No mice exhibited multiple tumors.

### Flow cytometry

Flow cytometry analysis of tumor infiltrated neutrophils in tumor tissues was performed as described previously ([@b26-ol-0-0-11701]). Tumor tissues were mechanically dissected into small pieces and further digested with a mixture of Liberase™ TL (Roche Applied Science) and DNase. Cells digested from the tumor tissues were filtered through a 70-µm filter, fixed with 4% paraformaldehyde at room temperature for 15 min, and incubated in PBS containing 1% FBS (cat. no. 10099141; Gibco, Thermo Fisher Scientific, Inc.) and 3 mM EDTA at room temperature for 20 min to block non-specific binding. The cells were incubated with an anti-mouse cluster of differentiation (CD) 16/32 antibody (2.5 µg/10^6^ cells; cat. no. MAB1460; R&D Systems, Inc.) at 4°C for 30 min. Cells were stained with fluorescein isothiocyanate-conjugated CD45 (0.25 µg/10^6^ cells; cat. no. 147709, Biolegend, Inc.); P-phycoerythrin-conjugated CD11b (0.25 µg/10^6^ cells; cat. no. 101207; Biolegend, Inc.) and APC-conjugated lymphocyte antigen 6 complex, locus G antibodies (0.06 µg/10^6^ cells; cat. no. 127613; Biolegend, Inc.) at 4°C for 30 min. Flow cytometry data acquisition was performed on a BD FACSCalibur (BD Biosciences) and analysed by FlowJo version 7.6 (BD Biosciences).

### Statistical analysis

All data are expressed as the mean ± SD from at least triplicate experiments. For the correlation analysis between B7-H4 and upregulated DEGs in TCGA data, the Pearson\'s correlation test was used. For the chemokine IHC score, the unpaired Student\'s t-test was used to evaluate the difference in two groups (dichotomized according B7-H4 level). For multiple groups in the mouse model, quantitative data was analysed by the one-way ANOVA. Multiple comparisons among the groups were performed using the Tukey\'s post hoc test. SPSS 19.0 software (IBM Corp.) was used for all statistical analysis. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Identification of DEGs in microarray datasets and functional enrichment analysis

To identify the effects of B7-H4 overexpression on the function of renal cell carcinoma cells, the total mRNA extracted from NC/786-O and B7-H4/786-O cells was subjected to microarray analysis. The heatmap of the gene expression in the two cell lines (triplicates of each cell line) is presented in [Fig. 1A](#f1-ol-0-0-11701){ref-type="fig"}. In total, 724 upregulated and 804 downregulated DEGs were obtained. The significantly enriched KEGG pathways of upregulated genes in the B7-H4/786-O cell line were analyzed. The KEGG pathways of upregulated genes with P≤0.01 are shown in [Fig. 1B](#f1-ol-0-0-11701){ref-type="fig"}. The results revealed that there was a significant association with 'rheumatoid arthritis', 'legionellosis', 'TNF signaling pathway', 'nucleotide-binding oligomerization domain (NOD)-like receptor signaling pathway', 'NF-κB signaling pathway' and 'chemokine signaling pathway' ([Fig. 1B](#f1-ol-0-0-11701){ref-type="fig"}). GO terms enrichment analysis for upregulated DEGs was performed. The top 20 biological processes (BPs) are presented in [Fig. 1C](#f1-ol-0-0-11701){ref-type="fig"}. The results revealed that 'inflammatory response', 'immune response', 'cell chemotaxis' and 'cellular response to lipopolysaccharide' were associated with the upregulated DEGs ([Fig. 1C](#f1-ol-0-0-11701){ref-type="fig"}).

### Verification of upregulated DEGs by B7-H4 via western blotting

By GO BP analysis, the predominant BPs of the upregulated DEGs were 'inflammatory response', 'immune response' and 'cell chemotaxis', all of which are associated with the immune characteristics of tumor cells. Further analysis of GO revealed that IL33, TLR2, CXCL1 and CXCL8 were involved in these BPs. The upregulated DEGs involved in these BPs are listed in [Table I](#tI-ol-0-0-11701){ref-type="table"}. Next, the protein level of upregulated DEGs in 786-O transfectants was verified using western blot analysis. [Fig. 2A](#f2-ol-0-0-11701){ref-type="fig"} revealed that the protein levels of NME1, MME, VNN1, MMP7, TNF, CXCL8, CXCL1 and CCL20 were upregulated in B7-H4/786-O cells compared with NC/786-O cells. To further confirm the effect of B7-H4 on the expression of these cytokines, the SK-BR-3 cell line was transfected with scramble small interfering (si)RNA and B7-H4 siRNA. Western blot analysis demonstrated that loss of B7-H4 in the SK-BR-3 cell line resulted in decreased MME, MMP7, CXCL8, CXCL1 and CCL20 ([Fig. 2B](#f2-ol-0-0-11701){ref-type="fig"}). Both overexpression and knocking down of B7-H4 in cancer cell lines confirmed that B7-H4 expression led to upregulation of the cytokines that were identified by microarray analysis.

### TCGA and IHC analyses reveal the upregulation of chemokines by B7-H4 in clinical renal carcinoma

To further confirm the upregulation of cytokines by B7-H4 in cancer cell lines, the present study analyzed chemokine gene expression in clinical kidney tumors. The RNA-sequencing data of TCGA were analysed using the GEPIA website ([@b10-ol-0-0-11701]). As presented in [Fig. 3A](#f3-ol-0-0-11701){ref-type="fig"}, B7-H4 mRNA was associated with increased CXCL1, CXCL2, CXCL3, CXCL8, MMP7 and CCL20 mRNA levels in renal papillary cell carcinoma. Although the correlations were not strong according to the R values, they were significant. These data further verified the results obtained in the cell lines. A total of 59 clinical renal carcinoma tissues were collected, and B7-H4, CXCL8 and CCL20 expression was evaluated by IHC staining. The patient characteristics are shown in [Table II](#tII-ol-0-0-11701){ref-type="table"}. B7-H4 high expression was associated with tumor grade. As shown in [Fig. 3B](#f3-ol-0-0-11701){ref-type="fig"}, representative specimens with high B7-H4 expression exhibited high levels of CCL20 and CXCL8, while specimens with low B7-H4 expression exhibited low levels of CCL20 and CXCL8. There was a positive association between CCL20 and CXCL8 levels with B7-H4 ([Fig. 3C](#f3-ol-0-0-11701){ref-type="fig"}). These data suggested that B7-H4 expression enhanced CCL20 and CXCL8 levels in clinical renal carcinoma.

### B7-H4 promotes tumor proliferation and infiltrating neutrophils by upregulating CXCL8

Since CXCL8 promoted tumor progression by recruiting tumor-associated neutrophils ([@b27-ol-0-0-11701]), the present study investigated the role of CXCL8 in the tumor promotion role of B7-H4. NC/786-O and B7-H4/786-O cell lines were inoculated into mice, and isotype IgG or anti-CXCL8 antibody were administered. The tumor growth curve is shown in [Fig. 4A](#f4-ol-0-0-11701){ref-type="fig"}. After 21 days, tumor tissues were isolated and the tumor weight was evaluated. [Fig. 4B](#f4-ol-0-0-11701){ref-type="fig"} revealed that overexpression of B7-H4 significantly promoted tumor growth when isotype IgG was administered. However, when administering anti-CXCL8 antibody, there was no difference between NC/786-O and B7-H4/786-O, suggesting that B7-H4 promoted tumor growth through CXCL8. The fold-change in B7-H4/786-O (isotype/anti-CXCL8) decreased more significantly than in NC/786-O ([Fig. 4C](#f4-ol-0-0-11701){ref-type="fig"}). The gating strategy of tumor-infiltrating CD11b^+^Ly6G^+^ neutrophils was shown in [Fig. 4D](#f4-ol-0-0-11701){ref-type="fig"}. The results demonstrated that, in the isotype IgG-treated group, the ratio of infiltrating neutrophils in B7-H4/786-O was significantly higher than in NC/786-O ([Fig. 4E and F](#f4-ol-0-0-11701){ref-type="fig"}), but in the anti-CXCL8-treated group, no difference in the number of infiltrated neutrophils existed between the two cell lines. This result suggested that overexpressed B7-H4 in tumors induced neutrophil recruitment through CXCL8.

Discussion
==========

B7-H4 is an important negative co-stimulatory molecule of the B7 family ([@b8-ol-0-0-11701],[@b9-ol-0-0-11701],[@b17-ol-0-0-11701]). B7-H4 protein expression is restricted to activated T cells, B cells, DCs and macrophages ([@b8-ol-0-0-11701]). Additionally, it has been reported that B7-H4 is upregulated in several types of cancer ([@b28-ol-0-0-11701]--[@b31-ol-0-0-11701]), which suggests that B7-H4 has the potential to be used as a biomarker or therapeutic target for tumors ([@b19-ol-0-0-11701],[@b31-ol-0-0-11701]--[@b33-ol-0-0-11701]). However, other studies revealed that B7-H4 promotes cell proliferation ([@b34-ol-0-0-11701],[@b35-ol-0-0-11701]), invasion and metastasis of tumor cells ([@b15-ol-0-0-11701],[@b35-ol-0-0-11701],[@b36-ol-0-0-11701]), enhances leukemia-initiating cell differentiation ([@b23-ol-0-0-11701]), and is correlated with carcinogenesis and chemoresistance ([@b34-ol-0-0-11701],[@b37-ol-0-0-11701]).

There are multiple mechanisms by which B7-H4 can affect tumor cell biology. Wang *et al* ([@b34-ol-0-0-11701]) reported that silencing B7-H4 enhances drug-induced apoptosis by inhibiting the phosphatase and tensin homolog (PTEN)/PI3K/AKT signaling pathway, indicating the role of B7-H4 in chemoresistance and suggesting that it may be an attractive therapeutic target in triple-negative breast cancer. Xie *et al* ([@b15-ol-0-0-11701]) demonstrated that B7-H4 induced epithelial-mesenchymal transition, and promoted invasion and metastasis of tumor cells by the activation of the ERK1/2 signaling pathway. Furthermore, upregulated B7-H4 expression was associated with downregulated Bax, upregulated Bcl-2 and activation of caspase-3 ([@b15-ol-0-0-11701]). Qian *et al* ([@b38-ol-0-0-11701]) analyzed the microRNA (miRNA) expression profile following B7-H4 knockdown in pancreatic cancer cell line L3.6p1 and noticed that the differentially expressed miRNAs induced by B7-H4 siRNA were mainly involved in the mitogen-activated protein kinase and PI3K/AKT signaling pathways. Chen *et al* ([@b37-ol-0-0-11701]) demonstrated that B7-H4 expression is positively correlated with IL6 expression and signal transducer and activator of transcription 3 phosphorylation. Xia *et al* ([@b23-ol-0-0-11701]) revealed that B7-H4 is one of the highly expressed immune molecules on human acute myeloid leukemia cells, and promotes the differentiation of leukemia-initiating cells through the PTEN/AKT/hypoxia-inducible factor-1α/REST corepressor 2/runt-related transcription factor 1 signaling pathway ([@b23-ol-0-0-11701]).

The present study constructed B7-H4 wild-type overexpressing cells to investigate the specific DEGs induced by B7-H4 wild-type in 786-O cells. The results revealed that there were 704 upregulated and 804 downregulated DEGs. The upregulated DEGs were associated with the inflammatory response, immune response and cell chemotaxis. Of the upregulated DEGs obtained by microarray, the upregulation of NME, MME, VNN1, MMP7, TNF, CXCL8, CXCL1 and CCL20 were confirmed by western blot analysis. Since all these molecules are involved in the inflammatory response, immune response and cell chemotaxis, the current study further examined the chemokine expression in clinical renal carcinoma by TCGA dataset analysis and IHC staining in 59 clinical tumor tissues. The results revealed that there was a positive correlation between B7-H4 and CCL20 or CXCL8. Furthermore, B7-H4 increased tumor-associated infiltrating neutrophils by upregulating CXCL8, indicating another mechanism in the tumor promoting effect of B7-H4. Similar the results obtained in the present study, Azuma *et al* ([@b39-ol-0-0-11701]) revealed a correlation between serum B7-H4 and neutrophil in peripheral blood from the patients with clear cell renal cancer. The present study demonstrated that B7-H4 expression increased tumor-infiltrating neutrophils by upregulating CXCL8 and that blocking CXCL8 reversed this increase. The present study revealed the molecular mechanism underlying the B7-H4-associated increase in tumor-infiltrating neutrophils, and suggested that B7-H4 and CXCL8 might serve as therapeutic targets to remodel the tumor microenvironment.

Besides CXCL8, the chemokine CCL20 is also upregulated in B7-H4-transfected cells. CCL20 is an 8-kDa protein involved in the maintenance of immunological homeostasis ([@b40-ol-0-0-11701]). T cells, natural killer (NK) cells, B cells and immature DCs are recruited to the tumor by the interaction of CCL20 with CCR6 ([@b41-ol-0-0-11701]--[@b43-ol-0-0-11701]). As CCL20 recruits both anti-tumor leukocytes and pro-tumor leukocytes (regulatory T cells, myeloid dendritic cells and NK cells), the role of CCL20 in tumor progression is complex ([@b44-ol-0-0-11701]). Tumor cells, macrophages and neutrophils produce CXCL1 and recruit myeloid-derived suppressor cells, which suppress the activity of CD8^+^ T effector cells to prevent tumor cell killing by CD8^+^ T cells ([@b44-ol-0-0-11701],[@b45-ol-0-0-11701]). Thus, upregulated CXCL1 expression by B7-H4 expression may contribute to tumor progression ([@b44-ol-0-0-11701]). Of the upregulated DEGs identified in the present study, MMP7 exhibited the largest fold-change difference. MMPs are a family of enzymes responsible for the degradation of a wide spectrum of extracellular matrix and non-matrix proteins ([@b46-ol-0-0-11701]). During carcinogenesis, MMPs can regulate the microenvironment and contribute to several critical steps in cancer development via their involvement in cell proliferation, differentiation, apoptosis, invasion, migration and immune surveillance ([@b46-ol-0-0-11701]--[@b48-ol-0-0-11701]). Thus, upregulated MMP7 expression by B7-H4 may serve an important role in tumor progression.

In conclusion, the results of the present study revealed that in renal cell carcinoma, B7-H4 may upregulate CXCL1, CXCL8, CCL20 and MMP7 and thus recruit tumor-associated neutrophils.
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![Identification of DEGs between NC/786-O and B7-H4/786-O cell lines by microarray analysis. (A) Heatmap of DEGs between NC/786-O and B7-H4/786-O cells. (Red, upregulated genes; green, downregulated genes and black, unchanged genes). (B) Significant KEGG signaling pathways (P≤0.01) of the upregulated genes are shown. No significant KEGG pathway was identified for the downregulated genes. (C) GO terms enrichment analysis of BPs. The top 20 BPs are shown. DEGs, differential expressed genes; NC, negative control; B7-H4, B7 family member, H4; KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological process; GO, Gene Ontology; WT, wild-type.](ol-20-02-1535-g00){#f1-ol-0-0-11701}

![Verification of the upregulated differentially expressed genes induced by B7-H4 expression in 786-O and SK-BR-3 cell lines. Western blot analysis was performed on the total protein extracted from (A) negative control/786-O and B7-H4/786-O cell lines and (B) scramble siRNA/SK-BR-3 and B7-H4 siRNA/SK-BR-3 cell lines. B7-H4, B7 family member, H4; siRNA, small interfering. As many proteins were examined, tubulin or actin were used as loading control for each protein depending on how to cut the PVDF membrane. In pre-experiments, we found that the expression level of tubulin was strictly parallel to actin in each cell line. So both of them could be used as loading control freely for each cell line.](ol-20-02-1535-g01){#f2-ol-0-0-11701}

![Association of B7-H4 with the differentially expressed genes is confirmed in clinical renal cell carcinoma tissues and TCGA datasets. (A) RNA-sequencing data of TCGA data analysed using the Gene Expression Profiling Interactive Analysis website. The correlation of B7-H4 gene in kidney renal papillary cell carcinoma was analysed using the Pearson\'s correlation test. (B) Immunohistochemical analysis of B7-H4, CCL20 and CXCL8 in clinical renal cell carcinoma tissues. Representative images are shown. Magnification ×400. Scale bar, 400 µm. (C) Statistical analysis of the CCL20 and CXCL8 levels in B7-H4^high^ and B7-H4^low^ tissues using the Student\'s t-test. \*\*P\<0.01. B7-H4, B7 family member, H4; TCGA, The Cancer Genome Atlas; CCL20, C-C motif chemokine ligand 20; CXCL8, C-X-C motif chemokine ligand.](ol-20-02-1535-g02){#f3-ol-0-0-11701}

![Evaluation of the effects of CXCL8 on the B7-H4-mediated promotion of tumor growth and tumor-infiltrating neutrophils. 786-O transfectants were inoculated into non-obese diabetic/severe combined immunodeficiency mice (n=6/group). (A) Tumor growth curve was evaluated by assessing tumor volume. The tumor volumes on day 21 showed significance, \*\*\*P\<0.001. (B) Tumor weight was evaluated after 21 days of treatment with isotype IgG or anti-CXCL8 antibody (n=6). (C) Fold-change of tumor weight between the isotype IgG and anti-CXCL8 antibody groups. (D) Gating strategy of CD11b^+^Ly6G^+^ in tumor tissues is shown. (E) Tumor-infiltrating neutrophils were analysed by flow cytometry. Cells from tumor tissues were stained with fluorescein conjugated CD45, CD11b and Ly6G. The ratio of CD11b^+^Ly6G^+^ in CD45^+^ cells was evaluated by flow cytometry. (F) Statistical analysis of the ratio CD11b^+^Ly6G^+^/CD45^+^ (n=6). Multiple comparisons among the groups were performed using the Tukey\'s post hoc test. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001, as indicated. CXCL8, C-X-C motif chemokine ligand; B7-H4, B7 family member, H4; CD, cluster of differentiation; Ly6G, lymphocyte antigen 6 complex, locus G.](ol-20-02-1535-g03){#f4-ol-0-0-11701}

###### 

Upregulated differentially expressed genes involved in the inflammatory response, immune response and cell chemotaxis.

  Gene symbol   Regulation (BW/NC)   FC (BW/NC)   Regulation (BW/BM)   FC (BW/BM)
  ------------- -------------------- ------------ -------------------- ------------
  IL33          Up                   379.026787   Up                   258.11453
  TLR2          Up                   34.398422    Up                   2.3269036
  CXCL1         Up                   34.114403    Up                   104.74504
  CXCL8         Up                   29.291115    Up                   125.44275
  CSF2          Up                   27.370817    Up                   142.67291
  CCL20         Up                   17.881693    Up                   26.53977
  CXCL2         Up                   15.134712    Up                   29.041739
  TNF           Up                   11.655401    Up                   14.347787
  NME5          Up                   11.342079    Up                   7.7392936
  VNN1          Up                   10.856487    Up                   10.219795
  IGF2          Up                   10.503797    Up                   7.646981
  MMP7          Up                   10.202435    Up                   3.5069153
  CXCL3         Up                   9.860397     Up                   24.532923
  PTGS2         Up                   9.696702     Up                   3.1078327
  MMP1          Up                   8.226387     Up                   12.556886
  CCL2          Up                   5.6037107    Up                   10.624764
  CXCL5         Up                   4.761648     Up                   5.3687253
  MME           Up                   3.3166819    Up                   5.5750117

BW, B7-H4 wild-type/786-O; NC, negative control/786-O; FC, fold-change; BM, B7-H4 nuclear localization sequence mutant/786-O; B7-H4, B7 family member, H4; up, upregulated.

###### 

Patient characteristics.

                           B7-H4 level              
  ------------------------ ------------- ---------- -------
  Age, years (mean ± SD)   57.6±9.8      60.3±8.3   0.267
    \<60                   14            14         0.260
    ≥60                    11            20         
  Sex                                               0.891
    Male                   15            21         
    Female                 10            13         
  Grade                                             0.010
    G1-2                   16            31         
    G3-4                     9             3        
  T stage                                           0.200
    T1-2                   17            28         
    T3-4                     8             6        

Statistical analysis using the Pearson chi-square test. B7-H4, B7 family member, H4; T, tumor.

[^1]: Contributed equally
